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Abstract
Sunitinib is a tyrosine kinase inhibitor approved for the treatment of multiple solid tumors.
However, cardiotoxicity is of increasing concern, with a need to develop rational mechanism
driven approaches for the early detection of cardiac dysfunction. We sought to interrogate
changes in cardiac energy substrate usage during sunitinib treatment, hypothesising that
these changes could represent a strategy for the early detection of cardiotoxicity. Balb/CJ
mice or Sprague-Dawley rats were treated orally for 4 weeks with 40 or 20 mg/kg/day suniti-
nib. Cardiac positron emission tomography (PET) was implemented to investigate alter-
ations in myocardial glucose and oxidative metabolism. Following treatment, blood pressure
increased, and left ventricular ejection fraction decreased. Cardiac [18F]-fluorodeoxyglucose
(FDG)-PET revealed increased glucose uptake after 48 hours. [11C]Acetate-PET showed
decreased myocardial perfusion following treatment. Electron microscopy revealed signifi-
cant lipid accumulation in the myocardium. Proteomic analyses indicated that oxidative
metabolism, fatty acid β-oxidation and mitochondrial dysfunction were among the top myo-
cardial signalling pathways perturbed. Sunitinib treatment results in an increased reliance
on glycolysis, increased myocardial lipid deposition and perturbed mitochondrial function,
indicative of a fundamental energy crisis resulting in compromised myocardial energy
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metabolism and function. Our findings suggest that a cardiac PET strategy may represent a
rational approach to non-invasively monitor metabolic pathway remodeling following suniti-
nib treatment.
Introduction
Sunitinib Malate (Sutent1) is a small molecule tyrosine kinase inhibitor (TKI) clinically
approved to treat gastrointestinal stromal tumors, metastatic renal cell carcinoma and pancre-
atic neuroendocrine cancers [1] and is currently being implemented in over 130 trials across
diverse cancer indications [2]. Sunitinib competes with adenosine triphosphate (ATP) binding
on several tyrosine kinases, including vascular endothelial growth factor (VEGF), platelet
derived growth factor (PDGF), Fms-like tyrosine receptor kinase-3 and adenosine monophos-
phate [AMP]-activated protein kinase (AMPK) amongst others [3, 4]. Thus, sunitinib is
thought to exert multiple effects on tumor growth, survival and angiogenesis. Despite wide-
spread clinical approval, a significant toxicity profile has been reported [5]. Moreover, it is
strongly contended that there has been a significant and widespread under-recognition of
sunitinib cardiotoxicity [6]. Sustained hypertension and deterioration in left ventricular ejec-
tion fraction (LVEF) are the most commonly reported cardiotoxicities, with congestive heart
failure (CHF) also observed [7–9]. The long term impact of sunitinib treatment on cardiovas-
cular function is still largely unknown, with no widespread structured protocols, guidelines or
follow-up programs focusing on cardiovascular care and survivorship-related issues in place
[10].
While the precise mechanisms underlying sunitinib-induced cardiotoxicity require full elu-
cidation, several causative factors have been implicated, particularly the role of AMPK inhibi-
tion and subsequent perturbations in cardiomyocyte energy metabolism. Sunitinib attaches to
the ATP binding pocket of receptor tyrosine kinases acting as a competitive inhibitor of ATP,
thus preventing activation and downstream signalling [8]. It has thus been shown to alter
energy homeostasis in cardiomyocytes, via inhibition of AMPK leading to energy-conserving
mechanisms due to stress conditions, with resultant defects in metabolism [4, 9, 11]. Neverthe-
less, it is likely (due to lack of drug specificity) that inhibition of other kinases may also be
involved in the development of cardiotoxicity [4, 12]. Sunitinib-mediated mitochondrial dys-
function leading to cardiotoxicity, as well as decreases in ATP production have also been
shown [7, 11, 13], ultimately suggesting that sunitinib exerts its cardiotoxic effects via per-
turbed kinase signalling related to energy metabolism.
Considering the impact of sunitinib on cardiomyocyte metabolism, we hypothesized that
plasticity in substrate usage could represent a novel marker of sunitinib cardiotoxicity. The
heart relies heavily on aerobic metabolism [14] and normally derives 60–70% of its energy
from β-oxidation of long chain fatty acids, with the remainder derived from carbohydrate
sources [15]. However, the heart is capable of re-modelling metabolic pathways as a result of
chronic pathophysiological conditions [16].
We sought to i) assess the utility of PET tracers to detect early pathologic changes in cardiac
metabolism, a hypothesis previously proposed [17, 18], and ii) investigate whether metabolic-
PET could inform proteomic mechanistic studies relating to sunitinib induced cardiotoxicity.
Glucose metabolism was monitored using [18F]-fluorodeoxyglucose ([18F]FDG) whilst [11C]
acetate was used to monitor oxidative metabolism and myocardial perfusion. Mechanistically
Cardiac Metabolic Remodeling in Response to Sunitinib
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driven proteomic, immunohistochemistry and electron microscopy (EM) analyses were fur-
ther implemented to unravel mechanistic aspects of the associated cardiotoxicity phenotype.
Materials and Methods
Animals
Female Balb/CJ mice (n = 36, 6–8 weeks, Charles River Laboratories, Sandwich, UK) and Spra-
gue-Dawley rats (n = 12, 8 weeks, Harlan, Horst, The Netherlands) were housed in groups of
3–5, maintained on a 12 hour light/dark cycle, with free access to standard rodent chow and
water. Animal experiments conformed to guidelines from Directive 2010/63/EU of the Euro-
pean Parliament on the protection of animals used for scientific purposes. Experiments were
licensed and approved by the National Animal Experiment Board/Regional State Administra-
tive Agency for Southern Finland (License: 4835/04.10.03/2011) or the Department of Health
and Children, Dublin, Ireland (License: B100/3654). Protocols were reviewed by University
College Dublin Animal Research Ethics Committee.
Animals were randomised and treated daily (Monday-Friday, 4 weeks, oral gavage) with 40
(mice) or 20 (rats) mg/kg sunitinib (Sequoia Research Products, Pangbourne, UK) reconsti-
tuted in sterile water. Vehicle control cohorts received sterile water. After 4 weeks animals
were humanely euthanized using CO2 overdose followed by cervical dislocation.
Physiological Measurements
Blood pressure and cardiac physiology parameters were assessed prior to and during treat-
ment. Blood pressure was measured using the tail cuff method, whilst echocardiography was
performed using the Vevo 7701 or 12001 ultrasound scanner in mice and rats respectively.
Positron Emission Tomography
The myocardial metabolic rate of glucose (MMRG) was assessed using [18F]FDG in mice.
[11C]Acetate-PET was used to determine myocardial perfusion and oxidative metabolism in
rats as previously described [19]. Pre- and “on-treatment” scans were performed in both
models. [18F]FDG-PET scans were performed at University College Dublin, Pre-Clinical
Imaging Core where cardiac imaging protocols for mice have been validated. [11C]Acetate
imaging was performed at Turku PET Centre, Finland. Rats were used for [11C]acetate imag-
ing as their larger size improves image resolution and tracer modelling. Cardiac imaging pro-
tocols using [11C]acetate have been established and robustly validated in rats at the Turku
PET centre.
Histopathology and Electron Microscopy Analyses
After 4 weeks hearts were collected for downstream analyses including histopathology and
EM. Haematoxylin and Eosin staining was performed using standard protocols. Masson’s
Trichrome staining was used to assess fibrosis, whilst apoptosis and myocardial microvessel
density were assessed using terminal deoxynucleotide transferase (TdT)-mediated dUTP
nick-end labelling (TUNEL) and anti-CD31 staining on formalin-fixed paraffin-embedded
tissue sections. Lipid droplet accumulation was assessed both by EM and Oil Red O (ORO)
staining.
Proteomic Analyses
Liquid chromatography tandem mass spectrometry (LC-MS/MS) was implemented to interro-
gate the effect of sunitinib on myocardial signalling pathways after 4 weeks of treatment in the
Cardiac Metabolic Remodeling in Response to Sunitinib
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mouse model. Enzyme-linked immunosorbent assay (ELISA) was used to detect Mitochondrial
Complex I in post-treatment myocardial lysates. Western blot analysis was used to confirm
proteomic findings (succinate dehydrogenase complex, subunit A (SDHA) and hydroxyacyl-
Coenzyme A dehydrogenase/3-ketoacyl-coenzyme A thiolase/enoyl-coenzyme A hydratase
(trifunctional protein), alpha subunit (HADHA)) and to determine levels of phosphorylated-
Acetyl co-enzyme A carboxylase (phospho-ACC), CD36 and hypoxia-inducible factor 1 alpha
(HIF-1α).
Please refer to S1 File for full protocols.
Statistical Analysis
For all experiments (except LC-MS/MS) a p-value of< 0.05 was deemed to be significant.
Data were analysed between or within groups with unpaired / paired tests as described further
in S1 File. Error bars are SEM unless stated otherwise. For LC-MS/MS analyses please refer to
detailed methods in S1 File.
Results
Sunitinib Compromises Cardiac Function in Two Independent Rodent
Models
Rodents were treated with the minimal dose at which robust anti-tumor efficacy has been
observed across a range of rodent xenograft models [3] taking into account human plasma
concentrations, drug-drug interactions and the prevalence of cardiac toxicities in the clinic
[20].
To confirm that sunitinib caused clinically relevant changes in cardiovascular function of
rodents, blood pressure and LVEF were monitored. In sunitinib treated mice, mean arterial
pressure (MAP) increased significantly within the first week of treatment from 79.5 mmHg to
96.6 mmHg (Fig 1A), remaining elevated throughout the study period whilst LVEF (Fig 1B)
fell significantly from an average of 68% (pre-treatment) to 61% (week 2) and 54% (week 4).
LVEF in all treated animals exhibited a decrease compared to pre-treatment. Similar results
were observed in a rat model where systolic blood pressure rose significantly from an average
of 117 mmHg to 135 mmHg within the first 5 days of sunitinib treatment (Fig 1C). All suniti-
nib treated rats displayed an increase in systolic blood pressure. LVEF also fell in this model
(Fig 1D), reaching significance at day 12. Some recovery was seen in treated animals towards
the end of the treatment period, representing adaptation that has been observed elsewhere in a
similar model [21]. Fractional shortening (S1A Fig), cardiac output (CO; S1B Fig) and heart
rate (Fig 1E) were additionally measured in the rat model, all showing significant decreases
during the treatment period.
Sunitinib Alters Cardiac Metabolism as Measured by Metabolic PET
PET was used to non-invasively assess the impact of sunitinib on myocardial metabolism. In
mice, PET was performed using [18F]FDG, a glucose analogue, to measure MMRG. In rats
Kmono values, calculated from [
11C]acetate-PET scans, were used to measure oxidative
metabolism.
MMRG in mice increased significantly 48–72 hours following commencement of treat-
ment, further increasing to 30% during the second week of treatment, before declining (Fig
2A). MMRG was significantly elevated in the sunitinib versus the vehicle group during the
treatment period. MMRG variability may be explained by the requirement to conduct rodent
Cardiac Metabolic Remodeling in Response to Sunitinib
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cardiac PET studies in the non-fasted state to ensure generation of a detectable myocardial
MMRG signal [22]. Pilot studies (data not shown) indicated that in the fasting state [18F]FDG
update was largely below the limit of detection. While this represents a technical limitation in
rodent imaging, clinical cardiac [18F]FDG-PET implements robust protocols to control patient
glucose levels.
Kmono values (measured using [
11C]acetate-PET) were significantly lower in the sunitinib
treated animals during the treatment period (Fig 2B), indicating a sustained decrement in
myocardial oxygen consumption.
Fig 1. Physiological effects of sunitinib in two rodent models. Effects of sunitinib treatment on MAP (A,
n = 9/group) and LVEF (B, n = 13/group) in female Balb/CJ mice. D-E) Effect of sunitinib treatment on systolic
blood pressure (C), LVEF (D) and heart rate (E) in female Sprague-Dawley rats (n = 6/group, Significant
difference between groups (unpaired t-test, *p<0.05 **p<0.01 ***p<0.001), Significant change from pre-
treatment values (paired t-test, †p<0.05 ††p<0.01 †††p<0.001). Error bars = SEM)
doi:10.1371/journal.pone.0169964.g001
Cardiac Metabolic Remodeling in Response to Sunitinib
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Sunitinib Treatment Induces a Significant Decrease in Myocardial
Perfusion
[11C]Acetate-PET was also used to determine myocardial perfusion in rats (Fig 2C–2E). Fol-
lowing 5 days of treatment, myocardial perfusion had decreased significantly compared to
pre-treatment values, by an average of 38% (Fig 2E). Decreases of up to 80% in individual ani-
mals were seen. Starting at day 12, some recovery was seen in treated animals, although perfu-
sion never returned to pre-treatment values.
Changes in Myocardial Structure, Apoptosis, Microvessel Density or
Fibrosis, are not Observed in Sunitinib Treated Animals
Following 4 weeks of treatment all animals were humanely euthanized and hearts collected for
post-mortem analyses. Myocardial structure, including hypertrophy, fibrosis, apoptosis and
Fig 2. Effect of sunitinib treatment on myocardial metabolism and perfusion measured by PET. A) Myocardial
metabolic rate of glucose (MMRG) (mice, n = 10/group), B) Kmono (rats, n = 6/group). C-E) The effects of sunitinib treatment
on overall perfusion of the myocardium in the rat model: (C) Representative images of the myocardium as seen in Carimas
software (version 2.7) which is used to select region of interest (ROI), subsequently used to construct 17 segment heat
maps for the 11C-Acetate data (rats) (D) which are used to determine global perfusion values. D) Representative pre- and
5 days post-treatment in one treated and one vehicle rat E) The effects of sunitinib treatment on overall perfusion of the
myocardium (rats, n = 6/group, * = significant difference between groups (unpaired t-test, p<0.05), Significant change from
pre-treatment (paired t-test, †p<0.05 ††p<0.01), bar* indicates significantly different overall on-treatment values (two-way
ANOVA p < 0.05) Error bars = SEM).
doi:10.1371/journal.pone.0169964.g002
Cardiac Metabolic Remodeling in Response to Sunitinib
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microvessel density were assessed. Sunitinib did not affect morphology of the myocardium in
either mice or rats (Fig 3A and 3B). In mice, overt pathologic cardiac fibrosis was not observed,
whilst TUNEL staining indicated no significant difference in levels of apoptosis (Fig 3C and
3D respectively). Microvessel density remained unchanged (Fig 3E and S2 Fig). EM analysis
indicated no effect on mitochondrial ultrastructure (Fig 3F).
Sunitinib Leads to Increased Presence of Lipid Droplets in the
Myocardium
EM analysis of mouse myocardium revealed a significantly higher (4.6-fold) number of lipid
droplets, clustering adjacent to the mitochondria in sunitinib treated animals (Fig 3G). ORO
staining confirmed this finding in rat myocardium, where the presence of neutral triglycerides
and lipids was approximately 8-fold higher in sunitinib treated animals (Fig 3H).
Sunitinib Treatment Perturbs Key Pathways Involved in Energy Balance
in the Myocardial Metabolic Proteome
To interrogate the impact of sunitinib treatment on an extended dynamic range of proteins,
LC-MS/MS and IPA1 (QIAGEN Redwood City, www.qiagen.com/ingenuity) was performed
on murine myocardial tissue extracts (harvested after 4 weeks of treatment) to identify patho-
physiological pathways significantly enriched following sunitinib treatment (See S3 and S4
Figs and S1 and S2 Tables for a full list of identified proteins, hierarchical clustering and PCA).
The top three canonical pathways perturbed were oxidative phosphorylation (p = 4.42E-
14), fatty acid β-oxidation I (p = 5.24E-13) and mitochondrial dysfunction (p = 7.88E-12).
These, along with other significantly enriched canonical pathways are shown in Fig 4A and 4B.
The number of identified proteins involved in each pathway is indicated by the “ratio” column
and identified proteins within the “top pathways” are listed in Fig 4C.
Significant regulatory networks identified by IPA to be affected by sunitinib were also
examined (those with a score > 20 and > 10 focus molecules), the most significant network
(score = 60 and focus molecules = 26) being centred on Mitochondrial Complex 1 (Fig 4D).
MS proteomic data have been deposited to the ProteomeXchange Consortium [23] via the
PRIDE partner repository [24] with dataset identifier PXD001888.
Validation and Confirmation of Key Proteomic Findings
Key sunitinib pathway effectors implicated by LC-MS/MS were confirmed by ELISA and
Western blot. A decrease in Mitochondrial Complex I (ELISA) (Fig 5A), in the hearts of
treated mice supported proteomic findings, implicating complex down-regulation as central
to the most significantly enriched network identified by IPA (Fig 4D). SDHA, a subunit of
Complex II, was decreased in myocardial tissue following treatment (S2 Table, Log2 relative
rank = -0.684); Western blot analysis showed a 50% reduction compared to vehicle (Fig 5B
and 5F). HADHA, a protein that mediates the mitochondrial fatty acid beta-oxidation path-
way, appeared to be perturbed in the cytosolic myocardial fraction of tissues of sunitinib
treated mice (S2 Table, Log2 relative rank = -1.069). However this observation was not con-
firmed via Western blot (Fig 5B and 5G).
To determine whether sunitinib treatment resulted in inhibition of AMPK (mouse model)
phospho-ACC, a known substrate of AMPK [11], was assessed. A 90% reduction (p< 0.05)
was observed in the hearts of sunitinib treated animals compared to vehicle (Fig 5B and 5C).
Due to the increase in myocardial lipid droplet accumulation, CD36, a protein required for
lipid delivery into cardiomyocytes, was assessed. We observed a 4-fold increase in the levels of
Cardiac Metabolic Remodeling in Response to Sunitinib
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Fig 3. Histopathologic assessment of rodent myocardium following sunitinib treatment. All error bars
represent SEM unless otherwise indicated. H&E staining in mice (A) and rats (B) Magnification as indicated,
scale bars (black) 100 μM and 50 μM respectively. C) Masson’s trichrome staining to assess fibrosis in the
myocardium of vehicle versus sunitinib treated mice (scale bars (black) represent 100 μm (left) and 50 μm
(right), magnification as indicated). D) TUNEL staining for the assessment of apoptosis in mice (40 ×
magnification; scale bar (black): 50μm. 1000 nuclei were counted per organ using ImageJ software. % TUNEL
Cardiac Metabolic Remodeling in Response to Sunitinib
PLOS ONE | DOI:10.1371/journal.pone.0169964 January 27, 2017 8 / 18
CD36 in the cardiac tissue of treated mice compared to controls (Fig 5B and 5E). Sunitinib
treatment did not impact HIF-1α (a marker of hypoxia) protein levels (Fig 5B and 5D).
Discussion
The burgeoning field of cardio-oncology is driven by cardiovascular complications that occur
as a direct result of cancer treatments. It is widely accepted that early recognition of cardiovas-
cular side effects is vital to allow long-term continuous therapy [25]. Considering the impact
of sunitinib on cardiac energy balance, we hypothesized that plasticity in cardiac energy
positive nuclei shown). E) Microvessel density in mice (CD31 immuno-staining). Representative images
shown; scale bar (black) 50 μm, x 40 magnification. Vascular density is expressed as % CD31 positive pixels
to total pixels captured in each image. F and G) EM analysis of cardiac tissue (mice) to determine the
presence of mitochondrial damage [high magnification; x 29000] (F) and the presence of lipid droplets (white
arrows) [lower magnification; ×11500] (G), scale bars as indicated ** p = <0.01, n = 4/group. H) ORO analysis
in rat heart cryosections to determine lipid droplet accumulation (black arrows indicate representative red lipid
droplets, scale bars represent 500 μm; magnification is ×5; n = 3/group. Quantification a.u, arbitrary units
**p < 0.01, compared with vehicle. Values are means ± SD).
doi:10.1371/journal.pone.0169964.g003
Fig 4. Proteomic analyses of sunitinib effects in myocardial tissue. The most significantly perturbed canonical pathways from (A)
crude membrane and (B) cytosolic fractions from sunitinib treated and control mouse myocardial tissue (n = 4/group) C) Proteins perturbed
in the three most significantly enriched canonical pathways. D) Ingenuity Pathway Analysis (IPA) to determine the most significantly
enriched network which is centred on Mitochondrial complex 1. Colour intensity indicates the degree of up- (red) or down- (green)
regulation. IPA predictions are shown in blue (predicted inhibition) and orange (predicted activation). Black indicates no predicted effect.
Continuous lines indicate a direct relationship between two proteins; a discontinuous line indicates indirect association.
doi:10.1371/journal.pone.0169964.g004
Cardiac Metabolic Remodeling in Response to Sunitinib
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metabolism could represent an early marker of cardiotoxicity. Cardiac PET was implemented
to investigate alterations in myocardial glucose and oxidative metabolism. We further imple-
mented robust and mechanistically driven proteomic and histochemical analyses to interro-
gate the effects of sunitinib on metabolic pathways and to further uncover aspects of the
sunitinib induced cardiotoxicity phenotype.
In both rat and mouse models, sunitinib treatment lead to the development of hypertension
and also to decreased LVEF, mirroring the effects of sunitinib seen in the clinic. PET during
Fig 5. Confirmation of proteomic findings in mouse myocardial tissue. A) ELISA to measure
Mitochondrial complex 1 levels in myocardial tissue lysates. B) Immunoblot analysis of lysates from the
cytosolic fraction of myocardial tissue from vehicle or sunitinib treated animals (n = 4/group) as described.
C-G) Densitometry assessment of the presented western blots as described (* p < 0.05, error bars represent
SEM).
doi:10.1371/journal.pone.0169964.g005
Cardiac Metabolic Remodeling in Response to Sunitinib
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the treatment period indicated early alterations in metabolism; increased glucose uptake and
metabolism (MMRG) in mice and decreased oxidative metabolism (Kmono) in rats, coupled
with decreased perfusion in the myocardium as early as 5 days following commencement of
treatment. Despite these apparent metabolic changes no differences were seen in the morphol-
ogy of the myocardium in treated animals (mice and rats) after 4 weeks of sunitinib treatment.
Nevertheless, lipid droplet accumulation was evident in both models after 4 weeks of sunitinib
treatment. LC-MS/MS data in mice corroborated the imaging findings insofar as metabolic
pathway markers appeared as those most significantly perturbed following sunitinib
treatment.
A limited number of rodent studies have reported perturbations in discrete cardiovascular
parameters following sunitinib treatment [20, 21, 26, 27]. A recent study suggested that left-
ventricular fractional shortening is significantly decreased in mice that had received 28 days of
sunitinib treatment [27]. However, to the best of our knowledge our study is the first demon-
stration of two concurrent ‘non-interventional’ rodent models which present with a clinically
relevant and early cardio-toxicity phenotype following sunitinib treatment in the absence of
non-physiologic perturbations such as transaortic constriction or chemical induction [7, 20].
Balb/CJ mouse and Sprague-Dawley rat models presented with increased blood pressure
accompanied by decreased LVEF (Fig 1). LVEF recovery was observed in the rat model after 3
weeks of treatment. Adaptation to sunitinib cardiovascular insult has been previously noted in
rat models [21]. Nevertheless, basic cardiac histology remained unchanged following sunitinib
treatment in both models, with no evidence of fibrosis or hypertrophy (Fig 3A–3C). These
data concur with previous studies [20, 21], although others have shown LV fibrosis in female
mice following sunitinib treatment [27]. As previously observed in vivo [7, 13] and in vitro
[28] no change in the incidence of apoptosis was evident in the myocardial tissue of sunitinib
treated animals (Fig 3D).
Implementing our mouse model, we observed that glucose uptake and metabolism, quanti-
fied by MMRG, increased after 48 hours of sunitinib treatment (earlier than any changes in
LVEF, which occurred after 2 weeks), suggesting a rapid shift in the balance of metabolites
available to, or being used by, cardiomyocytes. For example, a shift from fatty acid metabolism
to glucose improves oxygen efficiency for ATP synthesis [16]. As mentioned above, in the
mouse model, MAP increases and remains elevated whereby LVEF shows a continuous
decline. In parallel, MMRG is elevated above baseline for the first two weeks of treatment
before returning (almost) to pre-treatment values by Week 3. We hypothesise that early
changes in MMRG reflect metabolic substrate plasticity, whereby glucose metabolism
increases in response to stress (as seen in other disease states e.g. chronic hypertension [16]).
Nevertheless, as the fate of the tracer is ultimately unknown, we cannot rule out glycogen accu-
mulation as underpinning detectable MMRG increase [29]. Increased glycogen has been
shown to correlate with a relative increase in [18F]FDG uptake following ischemic injury in
swine hearts, suggesting that increased rates of glucose transport and/or phosphorylation are
important determinants of relative accumulation of glycogen [30]. Working heart studies
using radiolabelled isotopes in isolated hearts could be used to further interrogate these find-
ings. Although not significantly different from baseline elevated MMRG in vehicle treated ani-
mals was also observed which may reflect variations in glucose levels at time of imaging. Ex
vivo measurements of myocardial glucose uptake at each time point could provide further
insight. By Week 4 of treatment, while LVEF decline persists (indicating non-adaptation in the
mouse model) our data suggests that the myocardium has attempted to revert to fatty acid
metabolism; histological analyses revealed the presence of cardiac lipid droplets (Fig 3F and
3G). While lipid droplet accumulation is a phenomenon previously observed in vitro [28], to
the best of our knowledge, this is the first observation of cardiac lipid droplet accumulation
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following sunitinib treatment in vivo. However, over-accumulation of lipids in the myocar-
dium has been shown to correlate with cardiac dysfunction (“lipotoxic cardiomyopathy” [16,
31]) resulting in decreased fatty acid oxidation, accumulation of toxic lipid intermediates, and
contractile failure. This would explain the persistent reduced LVEF still observed at Week 4.
At least three mechanisms may be considered: 1) reduced fatty acid oxidation and oxidative
metabolism, as supported by proteomic data (discussed below); 2) reduced phospho-ACC (Fig
5B and 5C) which may contribute to the build-up of lipid deposits by increasing lipid synthesis
and inhibiting fatty acid oxidation; 3) increased presence of fatty acid transporter proteins (e.g.
CD36) (Fig 5B and 5E). Further studies are required to fully elucidate these pathways. Not-
withstanding that MMRG data is unavailable for the rat model, we nevertheless still observe
enhanced accumulation of lipid droplets in the rat heart (Fig 3H) even though LVEF largely
returns to normal by Day 26 in this model. These data suggest individual (or in this case, inter-
species) variability in the adaptation process, whereby despite perturbed cardiac metabolism,
some hearts retain the ability to adapt to sunitinib treatment. Further worked is warranted to
interrogate individual adaptation response.
It has previously been shown in vitro [32] and in recently published in vivo data that treat-
ment with sunitinib leads to myocardial oxidative stress [33]. Thus [11C]acetate-PET was per-
formed in rats to determine whether this tracer could detect early changes in myocardial
oxygen consumption. As acetate is fully metabolised in the TCA cycle and due to tight cou-
pling between the TCA cycle and oxidative phosphorylation, early clearance rate of [11C]ace-
tate after intravenous administration correlates strongly with myocardial oxygen consumption
[34]. Significantly reduced oxidative metabolism was observed in the sunitinib group over the
treatment period (Fig 2B).
The initial uptake of the [11C]acetate tracer is indicative of myocardial perfusion. Our
results indicate that treatment with sunitinib leads to a significant reduction in perfusion after
just 5 days of treatment, with a gradual recovery over the treatment period (Fig 2E). Myocar-
dial ischemia as a result of decreased perfusion (which has been reported in patients following
sunitinib treatment [35]) could also lead to perturbation of fatty acid oxidation and an accu-
mulation of lipids, with glucose becoming the primary substrate for both increased anaerobic
glycolysis and for continued (although diminished) oxidative metabolism. This metabolic
switch may be a prerequisite for continued energy production and cell survival [29]. As such,
our [11C]acetate data could suggest a reduction in metabolic rate and shift towards anaerobic
metabolism manifesting soon after commencement of sunitinib treatment. Further work is
required to assess this hypothesis. Interestingly, both myocardial ischemia and changes in car-
diac metabolism have been implicated in the appearance of clinical arrhythmias [35, 36]. Thus,
it is noteworthy that bradycardia was observed in the current study (Fig 1E). Sunitinib can
lead to a prolongation of the QT interval [37], which is often associated with low heart rates
[38]. This has previously been observed both in vitro and in preclinical and clinical settings
[26, 28, 39] although mechanisms are yet to be fully elucidated.
The perfusion imaging results observed in rats indicated that following the initial decrease
in perfusion, there was some recovery over the course of the treatment period. The effects of
sunitinib on microvessel density (using the CD31 marker) and myocardial hypoxia (using
HIF1α) in the mouse model were thus also investigated and no differences between vehicle
and sunitinib groups were apparent after 4 weeks of treatment. N.B. As the [11C]acetate-PET
perfusion data indicates recovery by 4 weeks this is not unexpected. Interestingly, up-regulated
PHD3 (Prolyl hydroxlase 3; a controller of HIF) expression has been observed in mouse myo-
cardial tissue following 7 days of sunitinib treatment [20], which supports our early observa-
tions, where perfusion was at its lowest. Elsewhere, up-regulation of HIF-1α gene expression
was observed following 21 days of sunitinib treatment, although Western blot analysis showed
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a non-significant increase of HIF1α in the nuclear content [40]. It has been suggested that car-
diovascular pericytes are a primary cellular target of sunitinib-mediated cardiotoxicity. In the
myocardium of sunitinib treated mice, decreases in PDGFR-β (pericyte marker) expression in
cardiac lysates, decreased co-localisation of pericytes with CD31 and concurrent coronary
microvessel tortuosity and vascular permeability have been reported [20]. The initial decrease
in perfusion in the rat model may therefore be indicative of the effect of sunitinib on pericytes
(through its known interaction with PDGF). Nevertheless, at 4 weeks, there was no difference
between CD31 expression between groups (Fig 3E) and perfusion had recovered almost to
baseline further indicating coronary vasculature recovery in these models. Finally, it must also
be considered that myocardial blood flow may be affected by overall cardiac performance. Car-
diac output (CO) measurements indicated a significant albeit modest decrease following 6
days of treatment (S1B Fig) in rats. Isolated heart studies combined with ex vivo analysis of
treated animals could confirm whether the decrease in perfusion reflects a reduction in cardiac
output, a compensatory effect due to reduced myocardial oxygen demand, or a direct effect on
coronary microvascular function. The long term effects of early changes in perfusion are cur-
rently unknown.
It has previously been reported that sunitinib may cause overt mitochondrial damage in
rodents and human cardiomyocytes [7, 11, 13]. In the current study, EM analysis indicated no
effect on mitochondrial ultrastructure (Fig 3F). It is unclear why this effect is not evident in
our models, however sex and mouse strain differences may be relevant here [27]. Sunitinib
induced decline in LVEF has been shown to be reversible in humans [41]. It is possible that
recovery may occur if mitochondrial structural integrity can be preserved. In our study, mice
that develop LVEF dysfunction, but maintain mitochondrial integrity may represent those
patients where treatment withdrawal would allow LVEF recovery. It will be important in the
future to confirm whether mitochondrial dysfunction is a primary or a secondary event in the
sunitinib induced cardiotoxicity sequela.
LC-MS/MS pathway analysis of myocardial tissue was performed to further provide mech-
anistic insight into the sunitinib-induced cardiotoxic phenotype. Top canonical pathways
perturbed were those involved in oxidative phosphorylation, fatty acid β-oxidation I, mito-
chondrial dysfunction and TCA Cycle II (Fig 4C). Additionally, IPA (confirmed by ELISA,
Fig 5A) indicated that the most significant network among those affected by sunitinib was
centred on Mitochondrial Complex 1, which plays an essential role in oxidative phosphoryla-
tion and generation of cellular ATP [42]. LC-MS/MS findings were further validated using
Western blot analysis: SDHA (a member of both the TCA cycle and oxidative phosphoryla-
tion pathways), was also down-regulated in myocardial tissue. As the heart relies on aerobic
oxidative substrate metabolism for the generation of ATP any decline in mitochondrial activ-
ity may lead to perturbation of respiratory pathways, decreased ATP production and ulti-
mately heart failure [43].
Future studies will include tissue collection at early time points to further inform mechanis-
tic interrogation of early toxicity pathways to better corroborate imaging data and also to per-
form [18F]FDG-PET imaging in both species. Moreover, given the lack of histological findings,
additional studies are required to clarify the relationship between hypertension, sunitinib, and
cardiomyopathy. Specifically, hypertensive models (either spontaneously hypertensive animals
or implementing interventional hypertensive agents) may elucidate whether sunitinib directly
(via perturbation of tyrosine kinases) or indirectly (via induced acute hypertension) causes
early increases in MMRG.
In the current study the mouse model was used for all mechanistic investigations to corrob-
orate [18F]FDG-PET data—a protocol established and validated in mice at the University Col-
lege Dublin Pre-clinical Imaging Core Facility Dublin. The rat model was subsequently
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implemented to determine whether [11C]acetate could be used to investigate additional effects
of sunitinib (on perfusion and oxidative metabolism) and whether it would be suitable as an
early imaging biomarker of toxicity. In this case PET protocols established and validated in
rats at the PET Centre, Turku, Finland were exploited. Data from the rat model suggests a
physiological adaption to prolonged sunitinib treatment following initial disruption (such
adaption has been reported previously in rats [21]) manifesting as recovery of LVEF and perfu-
sion over the course of the treatment period. Nevertheless, recovery in oxidative metabolism,
blood pressure or heart rate is not observed and there is lipid droplet accumulation in the myo-
cardium. There was no similar recovery in LVEF in the mouse model. These data may thus
recapitulate individual (or in this case, species) variability in the adaptation process, whereby
despite perturbed cardiac metabolism, some hearts retain the ability to adapt to sunitinib treat-
ment. Further work is warranted to interrogate individual/ species specific adaptation response
mechanisms.
Current ‘on treatment’ manufacturers’ guidelines mandate that oncology patients should
be monitored by electrocardiography and assessed for CHF and hypertension. In the clinic
LVEF assessment by echocardiography is the most common practice [44, 45]. Nevertheless,
quantifiable reductions in LVEF may underestimate true cardiac damage, as myocardium
compensatory reserve can allow for adequate ventricular output despite sub-clinical dysfunc-
tion. Data may be further confounded by inherent interpretation subjectivity [46, 47]. Thus,
echocardiographic evaluation of changes in LVEF may not represent an ideal method for
early evaluation of cardiotoxicities following cancer therapy as echocardiographic methods
provide little insight into drug mechanism. Thus, an effective strategy for the early, mecha-
nism driven detection of cardiac damage in the context of sunitinib treatment may be war-
ranted. Our data indicates that sunitinib induces early changes in myocardial metabolism
that precede the development of overt cardiotoxicity and supports the potential utility of PET
to monitor substrate remodeling pathways. The plausibility of this method is supported by a
2011 case study, following the sudden death of a patient 28 months after commencing TKI
combination therapy. The patient died from a sudden myocardial infarction with cardiogenic
shock, but retrospective analysis of sequential [18F]FDG-PET scans were indicative of cardiac
toxicity developing during the period of concomitant administration of TKIs [18]. Further
clinical studies are warranted to fully understand the role of cardiac metabolic pathway
remodeling and PET in the cardio-oncology setting, particularly relating to the early identifi-
cation of cardiotoxicities and their reversibility. This is especially important when consider-
ing the expected increase in the application of TKIs. Understanding the perturbations that
occur with sunitinib could help inform the design of personalized, targeted pharmacologic
therapy. There is little guidance on the most efficacious pharmacologic therapy, given limited
mechanistic understanding. Thus, if it is determined that there are major adverse changes in
oxidative stress or cardiac metabolism, use of medications which improve these axes (e.g.
beta blockers) may be the preferred cardioprotective strategies. This work could further
inform the development of newer cardioprotective strategies that specifically target and
improve metabolism.
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